Complacent About Discrimination”

Total Page:16

File Type:pdf, Size:1020Kb

Complacent About Discrimination” this week RONALDO AND COKE page 465 • RECOVERY TRIAL page 466 • EARLY RETIREMENT page 468 MARK THOMAS GMC “complacent about discrimination” An employment tribunal has ruled for and discrimination at Heatherwood and The GMC (above) is accused the fi rst time that the GMC discriminated Wexham Park Trust, now Frimley Health of failing to take racial against a doctor on the grounds of race. Trust. The trust accused him of bullying and discrimination into account Omer Karim, a consultant urologist threatening behaviour towards a colleague. when dealing with the case against Omer Karim (inset) referred to the GMC by his employers, was The trust referred him to the GMC in treated diff erently from a white doctor who 2014. The next year interim conditions was also under investigation, the Reading were placed on his practice, pending a employment tribunal held, and there was full investigation. These were lifted later no credible explanation for the diff erence. that year, but it took three more years for a The way the GMC dealt with some of the hearing to clear him of any misconduct. allegations suggested that the regulator was The tribunal heard that although black “looking for material to support allegations and other ethnic minority doctors made up LATEST ONLINE . rather than fairly assessing matters 29% of UK doctors they were the subject of presented,” the tribunal noted. 42% of employers’ complaints. UK graduate GP is liable only The tribunal said it was “concerned doctors from ethnic minorities were 50% for costs of harm related to her there was a level of complacency about the more likely to get a sanction or warning than advice in case of operation of discrimination in the work of their white peers. “wrongful birth,” GMC or that there might be discrimination Karim accused the GMC of a “callous say Supreme infecting the referral process.” It noted disregard for the truth and honesty.” He Court judges “the failure of all the witnesses to express added, “Right from the outset, the GMC saw Trieste’s mental how, if at all, the awareness of the over- me as a guilty black doctor. We doctors need healthcare model representation of [black and ethnic to work to change the system.” is under threat, minority] doctors in complaints to the GMC A GMC spokesperson said, “We are giving claim supporters was considered in the investigation process full consideration to the fi ndings.” of the community or whether discrimination may have been a Frimley trust said in a statement, “We based approach factor consciously or unconsciously in the want to be the best possible employer and Hancock comes allegations faced by the claimant.” we will continue doing everything we can to under renewed The tribunal heard that Karim, a specialist listen to staff and eliminate inequalities.” pressure from PM’s in prostate cancer and robotic surgery, Clare Dyer , The BMJ former chief aide blew the whistle on poor practice, bullying, Cite this as: BMJ 2021;373:n1595 the bmj | 26 June 2021 463 SEVEN DAYS IN Eight in 10 doctors experienced moral distress during pandemic, BMA survey fi nds Four fi ft hs of nearly 2000 doctors who responded to a BMA survey said the term “moral distress” resonated with their experiences of working during the pandemic, and over half said the same for “moral injury.” The BMA defi ned moral distress as the “psychological unease generated where professionals identify an ethically correct action to take but are constrained in their ability to take that action.” Moral injury, the BMA said, can arise where sustained moral distress leads to impaired function or longer term psychological harm. “Moral injury can produce profound guilt and shame, and in some cases also a sense of betrayal, anger, and profound ‘moral disorientation,’” it explained. Helen Fidler, deputy chair of the BMA’s Consultants Committee, said what was important was “being able to now name the struggles that many doctors are having and pinpoint exactly what needs to be done to alleviate them.” The BMA has called for extra investment in the NHS, better staffi ng, and emotional and psychological support for healthcare workers. Abi Rimmer , The BMJ Cite this as: BMJ 2021;373:n1543 Covid-19 Chaand Nagpaul, chair of BMA pharmacological interventions for a new members’ bill that Health secretary ordered council, said that compulsory such as ketamine as justification seeks to change the law on to disclose documents vaccination of healthcare staff for excessive police force, which assisted dying in Scotland, The UK information commissioner raised new ethical and legal is disproportionately cited in paving the way for the first ordered England’s Department implications and that efforts cases where black men die in law debate on prospective of Health and Social Care to should be focused on targeted enforcement custody. legislation in Holyrood for more disclose two briefing papers engagement. Any policy must than five years. Supported by forming part of Exercise Cygnus, avoid discrimination, he said, Assisted dying Dignity in Dying, the bill would which Moosa Qureshi, an NHS given that uptake of the vaccine Hancock wants “holistic” legalise assisted dying as a consultant haematologist, has was lower in some ethnic and informed debate choice for terminally ill, mentally been campaigning for since the minority groups. England’s health secretary, competent adults—a change pandemic started. The papers Matt Hancock, acknowledged supported by 87% of the public cover how the NHS and social care problems with the current law in Scotland. would cope if a major pandemic that prohibits assisted dying as overwhelmed resources. Qureshi well as the risks in changing it. He Prevention said in a blog, “By refusing to told the All Party Parliamentary NHS will offer “health provide a population triage Group for Dying Well, which MOTs” at vaccination sites protocol, both the Department opposes assisted suicide, that The NHS in England plans of Health and NHS England have assisted dying was a matter to offer “health MOTs” at arguably transferred blame—and for parliament to decide. “It is NHS vaccination services, legal liability—from politicians important that any debate that pharmacies, clinics, and other and corporate executives to Excited delirium we have [on assisted dying] is sites. Announcing the plan, NHS NHS healthcare workers who AMA opposes “excited nested in a wider debate about England’s chief operating officer, had already risked their lives on delirium” diagnosis how we support people better Amanda Pritchard, said that the the front line.” The government The American Medical towards the end of their lives,” aim was to make “every contact has 28 days to respond to the Association adopted a policy said Hancock. He pledged to help count” by rolling out tests such request. to oppose “excited delirium” improve the evidence base and as blood pressure, heart rhythm, as a medical diagnosis and accepted that palliative care and cholesterol checks when Mandatory vaccination to warn against using certain services needed further patients already have other could extend to NHS pharmacological interventions investment. appointments. Checks Staff in England’s care solely for a law enforcement will be offered when homes will be required to be purpose without a legitimate Bill is introduced in patients attend for top-up vaccinated against SARS-CoV-2 medical reason. It said that the Scottish parliament covid vaccinations or flu from October if legislation is new policy, adopted at the AMA’s Liam McArthur (right), vaccinations this autumn approved by parliament, and special meeting of its House of MSP for Orkney, lodged in locations such as village the government is set to consult Delegates, follows reports that proposals in the halls, churches, on whether to extend the showed a pattern of using the Scottish mosques, and local requirement to NHS workers. term “excited delirium” and parliament sports centres. 464 26 June 2021 | the bmj SIXTY SECONDS MEDICINE ON . RONALDO Antibiotics AND COKE Use on UK pig farms has more than doubled HAVE THEY TEAMED UP? Unpublished industry data show Quite the opposite. Cristiano Ronaldo—the that the use of aminoglycosides A steep rise in footballing superstar and global icon—has been widely praised by public health experts on UK pig farms rose from aminoglycoside aft er he shunned Coca-Cola during a press 2.607 mg/PCU (mg per kg of body use in piggeries conference at the UEFA Euro 2020 football weight) to 5.957 mg/PCU from raises fears of championships, where the soft drinks giant 2015 to 2019, raising concerns resistance is an offi cial sponsor. about the effect this could have on rise of antibiotic resistant AWKWARD. IS HE A PEPSI MAN? infections. Agricultural leaders management services, as well as Not as far as we’re aware (although he has have suggested a recent jump in a £30m enhanced service for GPs COVID advertised both brands in the past). But the use of aminoglycosides could to treat patients with long covid. aft er ostentatiously shift ing two bottles be because of the push to reduce DEATHS of Coke away from his vicinity during the other antibiotic use, as well as CPR press conference, the never shy nor retiring the upcoming EU ban on the use NHS offers training Peru ranks top Portugal captain held up a bottle of water before declaring, “Agua!”—encouraging of zinc oxide, which is commonly after footballer’s collapse in the world for people to choose the old H O instead. used to control scour (diarrhoea) The NHS and St John Ambulance deaths per million 2 in piglets. have joined forces to encourage population at TAP OR BOTTLED? people to learn cardiopulmonary He didn’t specify, so we can’t rule out Childbirth resuscitation and how to use 5864, with that he’s a secret agent for “Big Water.” Caesarean sections But given that he’s still in peak physical a defibrillator (below).
Recommended publications
  • (MGH) COVID-19 Treatment Guidance
    Version 8.0 4/28/2021 10:00AM © Copyright 2020 The General Hospital Corporation. All Rights Reserved. Massachusetts General Hospital (MGH) COVID-19 Treatment Guidance This document was prepared (in March, 2020-April, 2021) by and for MGH medical professionals (a.k.a. clinicians, care givers) and is being made available publicly for informational purposes only, in the context of a public health emergency related to COVID-19 (a.k.a. the coronavirus) and in connection with the state of emergency declared by the Governor of the Commonwealth of Massachusetts and the President of the United States. It is neither an attempt to substitute for the practice of medicine nor as a substitute for the provision of any medical professional services. Furthermore, the content is not meant to be complete, exhaustive, or a substitute for medical professional advice, diagnosis, or treatment. The information herein should be adapted to each specific patient based on the treating medical professional’s independent professional judgment and consideration of the patient’s needs, the resources available at the location from where the medical professional services are being provided (e.g., healthcare institution, ambulatory clinic, physician’s office, etc.), and any other unique circumstances. This information should not be used to replace, substitute for, or overrule a qualified medical professional’s judgment. This website may contain third party materials and/or links to third party materials and third party websites for your information and convenience. Partners is not responsible for the availability, accuracy, or content of any of those third party materials or websites nor does it endorse them.
    [Show full text]
  • Progress in the Development of Potential Therapeutics and Vaccines Against COVID-19 Pandemic
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 5 Issue 7 July 2021 Review Article Progress in the Development of Potential Therapeutics and Vaccines against COVID-19 Pandemic Abhishek Kumar Yadav, Shubham Kumar and Vikramdeep Monga* Received: May 02, 2021 Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, Published: June 09, 2021 India © All rights are reserved by Vikramdeep *Corresponding Author: Vikramdeep Monga, Department of Pharmaceutical Monga., et al. Chemistry, ISF College of Pharmacy, Moga, Punjab, India. Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 or coronavirus disease 2019 and the same has been declared as a global pandemic by WHO which marked the third introduction of a virulent coronavirus into human society. This a threat to human life worldwide. Considerable efforts have been made for developing effective and safe drugs and vaccines against is a highly pathogenic human coronavirus in which pneumonia of unknown origin was identified in China in December 2019 and is SARS-CoV-2. The current situation and progress in the development of various therapeutic candidates including vaccines in preclini- cal and clinical studies have been described in the manuscript. Until now, many people have been infected with this lethal virus, and a lot of people have died from this COVID-19. This viral disease spreads by coming in contact with an infected person. Understand- ing of SARS-CoV-2 is growing in relation to its epidemiology, virology, and clinical management strategies. Till date, very few drugs or vaccines have been developed or approved for the treatment of this deadly disease of COVID-19 and many candidates are under the clinical development pipeline.
    [Show full text]
  • Impact of SARS-Cov-2 Variant on the Severity of Maternal Infection and Perinatal Outcomes: Data from the UK Obstetric Surveillan
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.22.21261000; this version posted July 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Impact of SARS-CoV-2 variant on the severity of maternal infection and perinatal outcomes: Data from the UK Obstetric Surveillance System national cohort. Nicola Vousden PhD1, Rema Ramakrishnan PhD1, Kathryn Bunch MA1, Edward Morris MD2, Nigel Simpson MBBS3, Christopher Gale PhD4, Patrick O’Brien MBBCh,2,5, Maria Quigley MSc1, Peter Brocklehurst MSc6, Jennifer J Kurinczuk MD1, Marian Knight DPhil1 1National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK 2Royal College of Obstetricians and Gynaecologists, London, UK 3Department of Women's and Children's Health, School of Medicine, University of Leeds, UK 4Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London, London, UK 5Institute for Women’s Health, University College London, London, UK 6Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, UK *Corresponding author: Marian Knight National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK 01865 289700 [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2021.07.22.21261000; this version posted July 25, 2021.
    [Show full text]
  • An Examination of COVID-19 Medications' Effectiveness
    healthcare Review An Examination of COVID-19 Medications’ Effectiveness in Managing and Treating COVID-19 Patients: A Comparative Review Mahmoud Al-Masaeed 1,* , Mohammad Alghawanmeh 2, Ashraf Al-Singlawi 3 , Rawan Alsababha 4 and Muhammad Alqudah 1 1 Faculty of Health and Medicine, University of Newcastle, Callaghan 2308, Australia; [email protected] 2 Faculty of Pharmacy, Philadelphia University, Amman 19392, Jordan; [email protected] 3 Independent Scholar, Amman 11731, Jordan; [email protected] 4 School of nursing and Midwifery, Western Sydney University, Sydney 2560, Australia; [email protected] * Correspondence: [email protected] Abstract: Background: The review seeks to shed light on the administered and recommended COVID- 19 treatment medications through an evaluation of their efficacy. Methods: Data were collected from key databases, including Scopus, Medline, Google Scholar, and CINAHL. Other platforms included WHO and FDA publications. The review’s literature search was guided by the WHO Citation: Al-Masaeed, M.; solidarity clinical trials for COVID-19 scope and trial-assessment parameters. Results: The findings Alghawanmeh, M.; Al-Singlawi, A.; indicate that the use of antiretroviral drugs as an early treatment for COVID-19 patients has been Alsababha, R.; Alqudah, M. An useful. It has reduced hospital time, hastened the clinical cure period, delayed and reduced the Examination of COVID-19 need for mechanical and invasive ventilation, and reduced mortality rates. The use of vitamins, Medications’ Effectiveness in minerals, and supplements has been linked to increased immunity and thus offering the body a Managing and Treating COVID-19 fighting chance. Nevertheless, antibiotics do not correlate with improving patients’ wellbeing and Patients: A Comparative Review.
    [Show full text]
  • Official Report of This Meeting
    COVID-19 Committee Thursday 18 February 2021 Session 5 © Parliamentary copyright. Scottish Parliamentary Corporate Body Information on the Scottish Parliament’s copyright policy can be found on the website - www.parliament.scot or by contacting Public Information on 0131 348 5000 Thursday 18 February 2021 CONTENTS Col. CITIZENS PANEL ................................................................................................................................................ 5 SUBORDINATE LEGISLATION............................................................................................................................. 26 Personal Protective Equipment (Temporary Arrangements) (Coronavirus) (Scotland) Regulations 2021 (SSI 2021/50) ............................................................................................................. 26 Health Protection (Coronavirus) (Restrictions and Requirements) (Local Levels) (Scotland) Amendment (No 16) Regulations 2021 [Draft] ........................................................................................ 26 COVID-19 COMMITTEE 6th Meeting 2021, Session 5 CONVENER *Donald Cameron (Highlands and Islands) (Con) DEPUTY CONVENER Monica Lennon (Central Scotland) (Lab) COMMITTEE MEMBERS *Willie Coffey (Kilmarnock and Irvine Valley) (SNP) *Maurice Corry (West Scotland) (Con) *Annabelle Ewing (Cowdenbeath) (SNP) *John Mason (Glasgow Shettleston) (SNP) *Stuart McMillan (Greenock and Inverclyde) (SNP) *Mark Ruskell (Mid Scotland and Fife) (Green) *Beatrice Wishart (Shetland Islands) (LD)
    [Show full text]
  • Pandemic Planning , File Type: PDF, File Size
    July 2021 Dear ATISN 15194 – Pandemic Planning Thank you for your request to the Welsh Government for information under the Freedom of Information Act (2000) received on 03 June 2021. I have interpreted your requested information regarding pandemic planning as follows: 1. What plans were in place for a potential future pandemic before the COVID19 crisis began? 2. What conversations were had at ministerial level, before COVID19, about the potential of a future pandemic? 3. What plans are now in place for a future pandemic, if any? Our Response What plans were in place for a potential future pandemic before the COVID-19 crisis began? Wales, together with the rest of the UK, has been preparing its response to an influenza pandemic for many years. In 2007, Wales participated in the UK level (Tier 1) pandemic flu exercise Winter Willow, which led to the development of the 2007 National Framework for Responding to an Influenza Pandemic. This framework was used to support our Welsh Government response to the 2009 H1N1 Swine Flu pandemic. Although the H1N1 pandemic was not as severe as initially predicted, it did identify areas for further planning and Wales worked with the other UK governments to put in place the UK Influenza Preparedness Strategy 2011. This UK Strategy was agreed by the Health Ministers of all four nations. In 2016, our pandemic influenza plans were tested during Exercise Cygnus. The subsequent lessons identified were taken forward into an ongoing review of pandemic preparedness led by the UK Cabinet Office and Department of Health and Social Care.
    [Show full text]
  • COVID-Clinical-Update.Pdf
    COVID-19 Update Jorge Mera, MD Whitney Essex, APRN Questions • I have heard that the only thing that will end this pandemic is acquisition of immunity. That means either natural or by vaccination, therefore, in the absence of vaccination, we should be encouraging natural immunity (infection with recovery) rather than advocating avoidance. Any chosen path will result in casualties. however, our current path of avoidance is drawing out the process and hurting our nation. Please comment. • Prescriptions for zithromax and hydroxychloroquine have skyrocketed across the nation. Is there any role for these medications for outpatients, either prophylactically or for treatment? Please also discuss other treatments being advocated such as zinc. Dynamic interventions to control COVID-19 pandemic: a multivariate prediction modelling study comparing 16 worldwide countries • Non-pharmacological interventions (NPI) have been the mainstay for controlling the COVID-19 pandemic. • While NPIs are effective in preventing health systems overload, these long-term measures are likely to have significant adverse economic consequences • Many countries are currently considering to lift the NPIs • Dynamic NPIs, with intervals of relaxed social distancing, may provide a more suitable alternative, • But the ideal frequency and duration of intermittent NPIs, and the ideal “break” when interventions can be temporarily relaxed, remain uncertain • Multivariate prediction model, based on up-to-date transmission and clinical parameters, to simulate outbreak traJectories in 16 countries, from diverse regions and economic categories. • In each country, we then modelled the impacts on intensive care unit (ICU) admissions and deaths over an 18-month period for following scenarios: 1. No intervention 2. Consecutive cycles of mitigation measures followed by a relaxation period 3.
    [Show full text]
  • Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews
    Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews RAPID REVIEW – July 13th 2020. (The information included in this review reflects the evidence as of the date posted in the document. Updates will be developed according to new available evidence) Disclaimer This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. Yet, recognizing that there are numerous ongoing clinical studies, PAHO will periodically update these reviews and corresponding recommendations as new evidence becomes available. 1 Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews Take-home messages thus far: • More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. In this review we examined 26 therapeutic options. • Preliminary findings from the RECOVERY Trial showed that low doses of dexamethasone (6 mg of oral or intravenous preparation once daily for 10 days) significantly reduced mortality by one- third in ventilated patients and by one fifth in patients receiving oxygen only. The anticipated RECOVERY Trial findings and WHO’s SOLIDARITY Trial findings both show no benefit via use of hydroxychloroquine and lopinavir/ritonavir in terms of reducing 28-day mortality or reduced time to clinical improvement or reduced adverse events. • Currently, there is no evidence of benefit in critical outcomes (i.e. reduction in mortality) from any therapeutic option (though remdesivir is revealing promise as one option based on 2 randomized controlled trials) and that conclusively allows for safe and effective use to mitigate or eliminate the causative agent of COVID-19.
    [Show full text]
  • 27Th APRIL 2020
    27th APRIL 2020 19 COVID-19 REPORT SUMMARY • The number of confirmed deaths as a result of COVID-19 has now passed 200,000 with Johns Hopkins University confirming almost 2,980,053 cases worldwide. • On 25th April, the UK became the fifth country in the world to record 20,000 hospital deaths as a result of COVID- 19. The UK death toll currently stands at 20,732. • Several Muslim majority countries have now begun to soften COVID-19 measures in preparation for the holy month of Ramadan with Saudi Arabia, Egypt and Algeria all shortening curfews that had been in place. • Multiple US States and European countries have begun to ease lockdown restrictions having instituted plans to begin reopening shops. • The World Health Organisation has warned that Africa could see as many as 10 million cases of COVID-19 within three to six months. In the last 10 days alone, the continent has seen a 40% rise in new COVID-19 cases. • A second wave of locusts has descended on East Africa and the swarm is estimated to be 20 times bigger than the first invasion at the end of 2019. Amidst the COVID-19 global lockdown, pesticides and bio-pesticides usually sourced from countries such as Japan, Morocco and the Netherlands, have become more expensive and harder to obtain. Further to this, protective clothing worn when using pesticides have been taken for those combating this coronavirus outbreak. • The World Health Organisation has warned against introducing ‘immunity passports’ for people who have recovered from the COVID-19 virus, citing that ‘there is currently no evidence that people who have recovered from Covid-19 and have antibodies are protected from a second infection’.
    [Show full text]
  • COVID-19/SARS-Cov2: an Exploration
    COVID-19/SARS-CoV2: An Exploration How we act now INTERACTIVE DOWNLOADABLE PDF will build the future for our children An urgent invitation: • To question all that is happening before the chance is lost • To explore broader science, views and statistics • To research further A compilation of links to resources that will: • Help you to navigate the current situation • Help you to make informed decisions • Promote open debate and explore different views • Offer a starting point for further research • Introduce just the tip of the iceberg of the wealth of knowledge we can explore Photo by Monica Gozalo on Unsplash.com • June 2021 COVID-19/SARS-CoV2: An Exploration PLEASE NOTE: Any text you see coloured orange with an underline throughout this document, will be clickable live links to internal Sections or Pages within this document, or go to external reference websites. INTRODUCTION In response to the remarkable times we are living in, we have created this shareable, downloadable, interactive PDF Exploration document ( also found on-lineHERE ), a gathering of our extensive research into the covid pandemic and its effects on us all. We hope that it will enable and inspire you to research further if you choose to. We respect and appreciate that some of what you read and explore may challenge views you hold to be true at the moment, but we believe there are significant questions that need asking about the Covid19 narrative as it is. We all wish to make choices that will enable a full and healthy life for ourselves, our communities and our children, and that are right for now and for the future.
    [Show full text]
  • How the Nations Should Gear up for Future Pandemics?
    Electronic supplementary material: The online version of this article contains supplementary material. Cite as: Issac A, Vijay VR, Krishnan N, Jacob J, Stephen S, Radhakrishnan RV, Dhan- © 2021 THE AUTHOR(S) dapani M. How the nations should gear up for future pandemics? J Glob Health JOGH © 2021 ISGH 2021;11:03075. How the nations should gear up for future pandemics? VIEWPOINTS Alwin Issac1, VR Vijay1, Nadiya Krishnan1, Jaison Jacob1, Shine Stephen1, Rakesh Vadakkethil Radhakrishnan1, Manju Dhandapani2 1College of Nursing, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India 2National Institute of Nursing Education, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India ealth authorities from the city of Wuhan, China, informed World Health Organization (WHO) about an increase in pneumonia cases of unknown origin on December 31, 2019. Health authorities in China Hdetected novel coronavirus as the causative agent for the pneumonia cases and the virus was initially named “2019-nCoV”, which was later renamed as coronavirus disease 2019 (COVID-19). Owing to the virus virulence and its contagious nature, WHO declared novel coronavirus outbreak a public health emergency of international concern. With the steep rise in number of people infected with the virus outside China, WHO stated the eruption as a pandemic on March 11, 2020 [1]. Owing to the plight of wildlife habitat, poor health system, and global connectivity, COVID-19 wouldn’t be the last time a virus would jump from animal into humans To increase pandemic resil- and endanger humanity. The ever-rising trend of globalization and human migra- ience, nations must adhere to tion for trade, commerce, and tourism across the national borders has made it easy the fundamentals of universal for an outbreak to progress to a pandemic.
    [Show full text]
  • Cairney UK Coronavirus Policy 25000 14.7.20
    Paul Cairney [email protected] Draft: 14.7.20 The UK Government’s COVID-19 policy: assessing evidence-informed policy analysis in real time (using 25000 words) Abstract. In March 2020, COVID-19 prompted policy change in the UK at a speed and scale only seen during wartime. Throughout, UK government ministers emphasised their reliance on science and expertise to make the right choices at the right time, while their critics argued that ministers ignored key evidence and acted too little too late. Lessons from this debate should have a profound effect on future action, but only if based on a systematic analysis of policymaking as the problem emerged in real time. We should not confuse hindsight with foresight. To that end, I combine insights from policy analysis guides, policy theories, and critical policy analysis to frame this debate. I use the classic 5-step policy analysis structure - define the problem, identify solutions, use values to identify trade-offs, predict and compare outcomes, and recommend choices - to identify the politics of policymaking in complex systems. The pandemic exposes the need to act despite high ambiguity and uncertainty and low government control, using trial-and-error strategies to adapt to new manifestations of the problem, and producing highly unequal consequences for social groups. Lessons for the future will only have value if we take these policymaking limitations and unequal socioeconomic effects into account. Introduction: how should we characterise the UK government response? On the 23rd March 2020, the UK Government’s Prime Minister Boris Johnson declared: ‘From this evening I must give the British people a very simple instruction – you must stay at home’ (Johnson, 2020a).
    [Show full text]